Happy to hear your NP discussion is consistent with what you're reading here.
I would make the choice based in part on whether or not you have other health problems or family history or risks. All of them increase risk of opportunistic infections. Anti-TNFs probably increase skin cancer risk a little while others might not. Anti-TNFs have small risk for lupus-like reactions while the others less so. Rinvoq has risks of blood clots more than the others and for many, it raises cholesterol levels considerably. Things like those are what to weigh when making the decision. So if you have personal or family history of heart attacks or strokes, that would move Rinvoq down the list.
If you're quite healthy otherwise with very little risks, the anti-TNFs probably have the strongest track record for success and are a reasonable starting place.
If you're worried about
one or more risks with them, go to the Skyrizi/Stelara class. Very good safety profiles for them.
Skyrizi and Stelara are pretty similar in mode of action, in effectiveness, and in side effect profile. Skyrizi might be slightly better. But I personally hate it because of the incredibly repetitive, annoying ad campaign. Insurance might dictate one over the other. I think either would be fine.
I would reserve Rinvoq for only if you fail anti-TNFs or Skyrizi/Stelara. In fact, some of the FDA approval states that they are reserved for people who have failed a prior therapy such as an anti-TNF. I'm not sure whether failing Entyvio is enough to get approval to jump to Rinvoq.
Post Edited (beave) : 5/27/2024 11:09:19 PM (GMT-8)